https://www.selleckchem.com/pr....oducts/cp21r7-cp21.h
Introduction Hepatocellular carcinoma (HCC) is one of the most common and deadliest cancers worldwide. In recent years, several drugs have been approved in first- and second-line setting. Currently, several phase-III trials are ongoing with combinations of checkpoint inhibitors, tyrosine kinase inhibitors (TKI) and anti-angiogenic antibodies, which will most likely increase therapeutic options in frontline therapy in the near future.Areas covered This review summarizes the standard of care in first-line systemic therapy for patients
Aimer
Commentaire
Partagez
